BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

被引：0
|
作者：
Moreno-Aspitia, A.
Hillman, D. W.
Wiesenfeld, M.
Hobday, T. J.
Rowland, K. M.
Northfelt, D. W.
Tenner, K. S.
Palmieri, F. M.
Perez, E. A.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Mayo Clin, Rochester, MN USA
[3] Oncol Associates, Cedar Rapids, IA USA
[4] Carle Canc Ctr, Urbana, IL USA
[5] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22S / 22S
页数：1
相关论文
共 50 条
  • [41] Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
    Shigehira Saji
    BioDrugs, 2013, 27 : 469 - 478
  • [42] A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05-97
    Krop, I. E.
    Miller, K. D.
    Zon, R. T.
    Isakoff, S.
    Schneider, C. J.
    Yu, M.
    Johnson, C.
    Vaughn, L. G.
    Shonukan, O. O.
    Sledge, G. W., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC).
    Adjei, AA
    Mandrekar, S
    Marks, RS
    Hanson, LJ
    Aranguren, D
    Jett, JR
    Simantov, R
    Schwartz, B
    Croghan, GA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [44] Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Sparano, Joseph A.
    Vrdoljak, Eduard
    Rixe, Oliver
    Xu, Binghe
    Manikhas, Alexey
    Medina, Carlos
    Ventilari Da Costa, Susanne Crocamo
    Ro, Jungsil
    Rubio, Gonzalo
    Rondinon, Monica
    Perez Manga, Gumersindo
    Peck, Ronald
    Poulart, Valerie
    Conte, Pierfranco
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3256 - 3263
  • [45] A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer
    Yamada, Yasuhide
    Minami, Hironobu
    Fuse, Nozomu
    Ohtsu, Atsushi
    Kato, Ken
    Kiyota, Naomi
    Shimada, Yasushiro
    Doi, Toshihiko
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Fujiwara, Yutaka
    Ito, Yuichiro
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [46] A phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced non-small-cell lung carcinoma.
    Blumenschein, GR
    Gatzemeier, U
    Fossella, F
    Burk, K
    Reck, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9120S - 9120S
  • [47] Survival Data of Patients with Anthracycline- or Taxane-Pretreated or Resistant Metastatic Breast Cancer
    Barnett, Chad M.
    PHARMACOTHERAPY, 2009, 29 (12): : 1482 - 1490
  • [48] A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial
    Williamson, S.
    Moon, J.
    Huang, C.
    Wolf, G.
    Urba, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 286 - 286
  • [49] Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma
    Robert, C.
    Lassau, N.
    Angevin, E.
    Soria, J.
    Chami, L.
    Zarafana, E.
    Landreau, V.
    Schwartz, B.
    Armand, J.
    Escudier, B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 254 - 254
  • [50] A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results
    Elser, C.
    Siu, L.
    Winquist, E.
    Agulnik, M.
    Pond, G.
    Chin, S.
    Francis, P.
    Cheiken, R.
    Petrenciuc, O.
    Chen, E.
    EJC SUPPLEMENTS, 2006, 4 (12): : 18 - 18
12345